These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22017398)

  • 1. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
    Iwase Y; Maitani Y
    Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.
    Iwase Y; Maitani Y
    Mol Pharm; 2011 Apr; 8(2):330-7. PubMed ID: 21166471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
    Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
    J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
    Li H; Yuan D; Sun M; Ping Q
    Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
    Sadzuka Y; Hirotsu S; Hirota S
    Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
    Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
    Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
    [No Abstract]   [Full Text] [Related]  

  • 7. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
    Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
    Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
    Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
    J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
    Dadashzadeh S; Vali AM; Rezaie M
    Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
    Zhang L; Cao DY; Wang J; Xiang B; Dun JN; Fang Y; Xue GQ
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3347-61. PubMed ID: 24379067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
    Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
    Strock CJ; Park JI; Rosen DM; Ruggeri B; Denmeade SR; Ball DW; Nelkin BD
    J Clin Endocrinol Metab; 2006 Jan; 91(1):79-84. PubMed ID: 16263812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma.
    Iwase Y; Maitani Y
    Biol Pharm Bull; 2012; 35(6):975-9. PubMed ID: 22687542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
    Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
    Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog.
    Dubey N; Varshney R; Shukla J; Ganeshpurkar A; Hazari PP; Bandopadhaya GP; Mishra AK; Trivedi P
    Drug Deliv; 2012 Apr; 19(3):132-42. PubMed ID: 22428685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
    Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
    J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.
    Zhang Z; Yao J
    AAPS PharmSciTech; 2012 Sep; 13(3):802-10. PubMed ID: 22639238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.